Biomarin Pharmaceutical Inc (BMRN)
81.26
-0.91
(-1.11%)
USD |
NASDAQ |
Apr 26, 14:24
Biomarin Pharmaceutical Free Cash Flow (Quarterly): -9.213M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -9.213M |
| September 30, 2023 | 112.23M |
| June 30, 2023 | 47.33M |
| March 31, 2023 | -98.70M |
| December 31, 2022 | -29.57M |
| September 30, 2022 | 121.85M |
| June 30, 2022 | 28.19M |
| March 31, 2022 | -76.11M |
| December 31, 2021 | -33.18M |
| September 30, 2021 | 76.70M |
| June 30, 2021 | 56.53M |
| March 31, 2021 | 85.26M |
| December 31, 2020 | -53.25M |
| September 30, 2020 | 66.05M |
| June 30, 2020 | -5.748M |
| March 31, 2020 | -59.21M |
| December 31, 2019 | -3.499M |
| September 30, 2019 | 34.72M |
| June 30, 2019 | -61.03M |
| March 31, 2019 | -85.33M |
| December 31, 2018 | 7.295M |
| September 30, 2018 | -2.659M |
| June 30, 2018 | -56.38M |
| March 31, 2018 | -72.67M |
| December 31, 2017 | -25.28M |
| Date | Value |
|---|---|
| September 30, 2017 | -4.19M |
| June 30, 2017 | -28.98M |
| March 31, 2017 | -149.53M |
| December 31, 2016 | -51.78M |
| September 30, 2016 | -36.46M |
| June 30, 2016 | -71.31M |
| March 31, 2016 | -216.66M |
| December 31, 2015 | -169.66M |
| September 30, 2015 | -47.41M |
| June 30, 2015 | -48.45M |
| March 31, 2015 | -181.64M |
| December 31, 2014 | -51.67M |
| September 30, 2014 | -33.73M |
| June 30, 2014 | -51.98M |
| March 31, 2014 | -50.10M |
| December 31, 2013 | -38.75M |
| September 30, 2013 | -22.69M |
| June 30, 2013 | -17.23M |
| March 31, 2013 | -43.86M |
| December 31, 2012 | -1.909M |
| September 30, 2012 | -0.799M |
| June 30, 2012 | -10.90M |
| March 31, 2012 | -13.35M |
| December 31, 2011 | -90.19M |
| September 30, 2011 | -47.53M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-98.70M
Minimum
Mar 2023
121.85M
Maximum
Sep 2022
10.49M
Average
-3.499M
Median
Dec 2019
Free Cash Flow (Quarterly) Benchmarks
| Eli Lilly and Co | -1.963B |
| Merck & Co Inc | -743.00M |
| Pfizer Inc | 4.196B |
| Bristol-Myers Squibb Co | 3.922B |
| Moderna Inc | 402.00M |